2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2684

Real-world Comparative Study of Methotrexate vs Tocilizumab in Patients with Giant Cell Arteritis with Large Vessel Involvement
Abstract Number: 2685

Factors Contributing to Capturing Positive Findings on Temporal Artery Biopsy: An Australian Experience from Two Rheumatology Referral Centers
Abstract Number: 2686

Real Life Data over 4 Years from a Fast Track GCA Pathway in Coventry
Abstract Number: 2687

Clinicopathologic Associations in a Large International Cohort of Patients with Giant Cell Arteritis
Abstract Number: 2688

Comparisons of Strategies for Diagnostic Assessment in Giant Cell Arteritis: Results from an International Observational Cohort
Abstract Number: 2689

GM-CSF Pathway Signature Identified in Temporal Artery Biopsies of Patients with Giant Cell Arteritis
Abstract Number: 2690

Fast Track Clinic (FTC) for Giant Cell Arteritis (GCA) – the United States Experience
Abstract Number: 2691

Treatment Patterns, Disease Burden and Outcomes in Patients with Giant Cell Arteritis and Polymyalgia Rheumatica
Abstract Number: 2692

Coronary Artery Disease in a Population-Based Cohort of Biopsy-Proven Giant Cell Arteritis in Southern Sweden
Abstract Number: 2693

Increasing Use of Biologics over Time in the First Year After Diagnosis of Systemic JIA Among Patients Enrolled in the Childhood Arthritis & Rheumatology Research Alliance (CARRA) Registry
Abstract Number: 2694

Inpatient Treatment Variation in New-Onset Systemic Juvenile Idiopathic Arthritis
Abstract Number: 2695

Early Treatment with Anakinra in Systemic Juvenile Idiopathic Arthritis
Abstract Number: 2696

Long-Term Efficacy and Safety of Сanakinumab in Children with Systemic Juvenile Idiopathic Arthritis
Abstract Number: 2697

Risk Score of Macrophage Activation Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis
Abstract Number: 2698

Reasons for Initiation of Canakinumab of Patients with Systemic Juvenile Idiopathic Arthritis: A Retrospective Medical Chart Review from the United States

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].